Marc Beer’s career path shows his outstanding leadership skill and commitment in the pharmaceutical field. Early 2000, he was appointed as the founding chief executive officer of ViaCell. The biotechnology company grew tremendously under his leadership managing to employ over three hundred workers. ViaCell Company mainly specializes in collecting umbilical cord blood stem cell, preserving and developing. After working for five years, Marc managed to move ViaCell Company publicly by 2005; two years later it was acquired by PerkinElmer.
Erytech Pharma appointed Mark as one of the boards of director members while working at ViaCell. Before he had joined ViaCell, he previously worked for the Genzyme. He used his expertise in sells and marketing in launching the company products. He has also served for many companies as founding chairman including Good Start Genetics, Minerva Neuroscience and as the advisory council of Miami University. Marc Beer is a graduate of Miami University with a bachelor of science degree.
His vast experience and expertise in pharmaceutical, biotechnology, innovation, and disease diagnosis were motivating factors to partner with Dr. Pulliam, Roman Iglesias, and Yolanda Lorie and started their company, Renovia. Mark shows the compassion in his duty by raising $42 million for finding the solution with regards to women health. He uses his innovation to find a product that will cure pelvic floor disorders.
The Pelvic floor disorders are as the result of the injury or weakening of the ligament, tissue and pelvic muscle. The condition is caused by the prolapse of the bladder, the urethra, rectum, and small intestine. Renovia Medtech Company is fully committed in research and find a product to diagnose the disorders. They estimate to reach around 250 million women across the globe. The company is looking for an exclusive way to train patient and strengthen the weak pelvic floors muscle while the patient is alone at home by investing in leva pelvic digital health system. Leva is their first product, and by April FDA approved it.
Leva product is visualized with technology that trains the patient to control urination. It has motion sensor technology that shows a vaginal profile of a woman when at rest or during movement, it is programmed to measure the time one requires during training, and it is easy for a patient to track and do a subsequent reading and share data using this technology. With the leva treatment, one requires no surgeries.
The funding from the Long wood is going to be used in developing of four products. Mark during an interview noted that the Renovia Company is appreciating the investors who willing are offering support to Boston based Medtech and it is so committed to provide treatment and change millions of lives of pelvic floor disorders patient in the world. Learn more: https://www.linkedin.com/in/marcbeer